Galecto Inc (GLTO)

Feb 15, 2025

Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World

Feb 15, 2025

Feb 12, 2025

Galecto stock hits 52-week low at $4.39 amid market challenges - MSN

Feb 12, 2025

Feb 12, 2025

Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World

Feb 12, 2025

Feb 11, 2025

Galecto to Participate in Upcoming Investor Conferences - The Globe and Mail

Feb 11, 2025

Feb 11, 2025

Galecto stock hits 52-week low at $4.39 amid market challenges By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Leerink Partnrs Estimates Galecto FY2024 Earnings - Defense World

Feb 11, 2025

Feb 08, 2025

Brokers Set Expectations for Galecto FY2029 Earnings - Armenian Reporter

Feb 08, 2025

Feb 06, 2025

Galecto to Participate in Upcoming Investor Conferences -February 06, 2025 at 08:01 am EST - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

Biotech Spotlight: Galecto Lines Up Triple Conference Showcase for Investors - StockTitan

Feb 06, 2025

Feb 01, 2025

Where are the Opportunities in (GLTO) - Stock Traders Daily

Feb 01, 2025

Jan 24, 2025

Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga

Jan 24, 2025

Jan 23, 2025

Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World

Jan 23, 2025

Jan 22, 2025

(GLTO) On The My Stocks Page - Stock Traders Daily

Jan 22, 2025

Jan 17, 2025

Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga

Jan 17, 2025

Jan 13, 2025

Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World

Jan 13, 2025

Jan 07, 2025

Galecto CEO Hans T. Schambye sells $7,509 in shares - Investing.com

Jan 07, 2025

Jan 03, 2025

Galecto (NASDAQ:GLTO) Shares Up 22.6% – Should You Buy? - Defense World

Jan 03, 2025

Jan 01, 2025

When (GLTO) Moves Investors should Listen - Stock Traders Daily

Jan 01, 2025

Dec 18, 2024

Galecto stock plunges to 52-week low at $4.78 amid market challenges - Investing.com Australia

Dec 18, 2024

Dec 12, 2024

Galecto stock hits 52-week low at $5.26 amid market challenges - Investing.com Nigeria

Dec 12, 2024

Dec 12, 2024

Galecto stock hits 52-week low at $5.26 amid market challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 09, 2024

(GLTO) Trading Signals - Stock Traders Daily

Dec 09, 2024

Nov 27, 2024

Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia

Nov 27, 2024

Nov 26, 2024

GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com

Nov 26, 2024

Nov 25, 2024

Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail

Nov 25, 2024

Nov 25, 2024

Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR

Nov 25, 2024

Nov 23, 2024

Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 23, 2024

Nov 22, 2024

GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 19, 2024

Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World

Nov 19, 2024

Nov 15, 2024

Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India

Nov 15, 2024

Nov 12, 2024

Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy

Nov 12, 2024

Nov 12, 2024

Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic

Nov 12, 2024

Nov 08, 2024

(GLTO) Investment Report - Stock Traders Daily

Nov 08, 2024

Nov 06, 2024

Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN

Nov 06, 2024

Nov 02, 2024

Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN

Nov 02, 2024

Nov 02, 2024

Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN

Nov 02, 2024

Nov 01, 2024

Galecto Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 01, 2024